G&S Capital LLC Apellis Pharmaceuticals, Inc. Transaction History
G&S Capital LLC
- $218 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding APLS
# of Institutions
337Shares Held
111MCall Options Held
1.26MPut Options Held
1.14M-
Wellington Management Group LLP Boston, MA15.1MShares$546 Million0.16% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.4MShares$412 Million19.04% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$403 Million7.87% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.51MShares$344 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.49MShares$199 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.98B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...